Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the company. Oppenheimer decreased their target price on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research report on Wednesday, June 12th. JMP Securities reiterated a market outperform rating and issued a $6.00 target price on shares of Cellectis in a research report on Friday, May 31st.

Cellectis Price Performance

Shares of Cellectis stock opened at $2.14 on Friday. The stock’s 50-day simple moving average is $2.73 and its 200-day simple moving average is $2.81. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The company has a market capitalization of $118.94 million, a price-to-earnings ratio of -1.66 and a beta of 3.09. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.69.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.64) EPS for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The business had revenue of $1.99 million during the quarter. As a group, analysts expect that Cellectis will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. lifted its stake in Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 424,533 shares of the biotechnology company’s stock after purchasing an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent reporting period. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.